Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

AUTL

Autolus Therapeutics plc ADR

May 15 • 03:19PM ET

3.95

Dollar change +0.02
Percentage change 0.51	%

Healthcare • Biotechnology • United Kingdom • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.20	Insider Own	9.38%	Shs Outstand	174.10M	Perf Week	-3.89%
Market Cap	687.70M	Forward P/E	-	EPS next Y	-0.57	Insider Trans	0.00%	Shs Float	157.78M	Perf Month	-18.72%
Income	-208.38M	PEG	-	EPS next Q	-0.08	Inst Own	69.15%	Short Float	2.23%	Perf Quarter	-45.52%
Sales	1.70M	P/S	404.53	EPS this Y	42.59%	Inst Trans	-1.84%	Short Ratio	2.26	Perf Half Y	7.92%
Book/sh	0.64	P/B	6.17	EPS next Y	17.38%	ROA	-48.14%	Short Interest	3.52M	Perf Year	56.75%
Cash/sh	1.38	P/C	2.86	EPS next 5Y	-	ROE	-101.61%	52W Range	2.01 - 7.45	Perf YTD	-38.66%
Dividend Est.	5.00 (126.58%)	P/FCF	-	EPS past 5Y	3.32%	ROI	-63.09%	52W High	-46.98%	Beta	2.01
Dividend TTM	-	Quick Ratio	6.11	Sales past 5Y	152.23%	Gross Margin	-286.63%	52W Low	96.52%	ATR (14)	0.30
Dividend Ex-Date	-	Current Ratio	6.11	EPS Y/Y TTM	23.64%	Oper. Margin	-10337.34%	RSI (14)	35.01	Volatility	6.67% 7.12%
Employees	463	Debt/Eq	2.01	Sales Y/Y TTM	-72.59%	Profit Margin	-12272.26%	Recom	1.36	Target Price	10.69
Option/Short	Yes / Yes	LT Debt/Eq	1.96	EPS Q/Q	-92.78%	Payout	-	Rel Volume	0.52	Prev Close	3.93
Sales Surprise	-100.00%	EPS Surprise	-68.25%	Sales Q/Q	-100.00%	Earnings	May 14 BMO	Avg Volume	1.56M	Price	3.95
SMA20	-5.47%	SMA50	-22.36%	SMA200	-11.98%	Trades		Volume	730,110	Change	0.51%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-09-23	Initiated	Deutsche Bank	Buy	$10
Mar-27-23	Resumed	Wells Fargo	Overweight	$8
Mar-17-23	Initiated	Bryan Garnier	Buy	$5
Jun-14-21	Upgrade	Jefferies	Hold → Buy	$6 → $12
Jan-29-21	Downgrade	JP Morgan	Overweight → Neutral	$9
Dec-28-20	Resumed	H.C. Wainwright	Buy	$19
Jul-31-20	Initiated	JP Morgan	Overweight
Jul-22-20	Initiated	SunTrust	Buy	$38
Apr-22-20	Initiated	Mizuho	Buy	$18
Sep-23-19	Initiated	Needham	Buy	$26
May-17-19	Reiterated	H.C. Wainwright	Buy	$45 → $41
Oct-24-18	Initiated	H.C. Wainwright	Buy	$45

Show Previous Ratings

May-14-24 10:00AM	Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress (GlobeNewswire)
May-13-24 11:15AM	Autolus Therapeutics Announces Delay of Q1 Earnings Release (MT Newswires)
07:00AM	Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call (GlobeNewswire)
Apr-24-24 10:00AM	Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO (GlobeNewswire) -6.03%
Apr-23-24 07:00AM	Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 (GlobeNewswire)
07:00AM	Loading…
Apr-02-24 07:00AM	Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL) (GlobeNewswire)
Apr-01-24 07:00AM	Autolus Therapeutics Announces Changes to its Board of Directors (GlobeNewswire) -10.97%
Mar-21-24 01:43AM	Q4 2023 BioNTech SE Earnings Call (Thomson Reuters StreetEvents)
Mar-17-24 09:19AM	Autolus Therapeutics plc (NASDAQ:AUTL) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-15-24 05:53AM	Q4 2023 Autolus Therapeutics PLC Earnings Call (Thomson Reuters StreetEvents)
Mar-14-24 01:51PM	Autolus Therapeutics PLC Reports Full Year 2023 Financial Results (GuruFocus.com)
07:00AM	Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates (GlobeNewswire)
Mar-12-24 07:00AM	Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site (GlobeNewswire)
Mar-11-24 07:00AM	Autolus Therapeutics announces publication in Blood Cancer Journal (GlobeNewswire) -5.25%
Mar-09-24 01:09PM	12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds (Insider Monkey)
07:00AM	Loading…
Feb-29-24 07:00AM	Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024 (GlobeNewswire)
Feb-22-24 07:00AM	Autolus Therapeutics announces publication in Nature Communications (GlobeNewswire)
Feb-12-24 02:29AM	Strength Seen in Autolus Therapeutics PLC Sponsored ADR (AUTL): Can Its 6.3% Jump Turn into More Strength? (Zacks) +9.56%
Feb-08-24 07:00AM	Autolus Announces Pricing of Underwritten Offering (GlobeNewswire) -5.06%
06:07AM	BioNTech partners with Autolus to boost cell therapy manufacturing (BioPharma Dive)
05:45AM	BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs (GlobeNewswire)
Jan-23-24 07:00AM	Autolus Therapeutics announces publication in ACS Chemical Biology (GlobeNewswire)
Jan-22-24 07:00AM	Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL) (GlobeNewswire) -5.89%
Jan-10-24 07:00AM	Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors (GlobeNewswire)
Dec-22-23 07:00AM	Autolus Therapeutics Announces Changes to its Board of Directors (GlobeNewswire)
Dec-18-23 02:58PM	12 Most Promising Cancer Stocks According to Analysts (Insider Monkey)
Dec-09-23 08:30PM	Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 (GlobeNewswire)
Nov-27-23 07:00AM	Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL) (GlobeNewswire)
Nov-15-23 07:00AM	Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023 (GlobeNewswire) +7.34%
Nov-06-23 07:00AM	Autolus Therapeutics announces participation in upcoming conferences (GlobeNewswire) -9.54%
05:34PM	Loading…
Nov-05-23 05:34PM	Autolus Therapeutics plc (NASDAQ:AUTL) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 09:00AM	Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 in Two Oral Presentations and Two Poster Presentations (GlobeNewswire) +14.92%
07:11AM	Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates (GlobeNewswire)
Oct-17-23 07:00AM	Autolus Therapeutics to host virtual event to discuss the company's obe-cel program in systemic lupus erythematosus (GlobeNewswire) +7.26%
Oct-11-23 08:07AM	Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023 (GlobeNewswire)
07:00AM	Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023 (GlobeNewswire)
Sep-05-23 07:00AM	Autolus Therapeutics announces data from AUTO1/22 trial in pediatric Acute Lymphoblastic Leukemia published in the journal Blood (GlobeNewswire) -5.99%
Aug-07-23 04:32PM	Autolus Therapeutics plc (NASDAQ:AUTL) Q2 2023 Earnings Call Transcript (Insider Monkey) -5.30%
Aug-04-23 06:29AM	Autolus Therapeutics (NASDAQ:AUTL) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Aug-03-23 07:00AM	Autolus Therapeutics Reports Second Quarter 2023 Financial Results and Operational Progress (GlobeNewswire)
Jul-19-23 07:00AM	Autolus Therapeutics announces appointment of Robert F. Dolski as Chief Financial Officer (GlobeNewswire) +5.06%
Jul-18-23 07:00AM	Autolus Therapeutics to report second quarter 2023 financial results and host conference call on August 3, 2023 (GlobeNewswire)
Jul-06-23 07:00AM	Autolus Therapeutics announces a publication in Nature Medicine on obe-cel in Pediatric Acute Lymphoblastic Leukemia (GlobeNewswire)
Jun-27-23 07:00AM	Autolus Therapeutics announces publication in Cancer Immunology Research (GlobeNewswire)
Jun-20-23 07:00AM	Autolus Therapeutics strengthens its Board with the appointment of Dr. Robert Iannone as a Non-Executive Director (GlobeNewswire)
Jun-16-23 07:00AM	Autolus Therapeutics Presents Positive Results from AUTO4 in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma (GlobeNewswire)
Jun-14-23 09:39AM	3 Top Penny Stock Picks You Havent Heard Of (InvestorPlace)
Jun-06-23 07:00AM	Autolus to hold Annual General Meeting (AGM) of Shareholders on Friday, June 30, 2023 (GlobeNewswire)
Jun-04-23 07:11AM	10 Hot Penny Stocks To Buy (Insider Monkey)
Jun-02-23 07:00AM	Autolus Therapeutics Presents Positive Results from Pivotal Phase 2 FELIX study in adult r/r B-ALL at ASCO (GlobeNewswire) -7.35%
May-22-23 07:00AM	Autolus Therapeutics to hold Analyst call to highlight data at ASCO from the Pivotal Phase 2 FELIX study of obe-cel data in adult r/r B-ALL (GlobeNewswire) +8.84%
May-12-23 07:00AM	Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at EHA (GlobeNewswire) +10.81%
May-04-23 07:00AM	Autolus Therapeutics Reports First Quarter 2023 Financial Results and Operational Progress (GlobeNewswire)
May-01-23 10:15AM	Autolus (AUTL) Selects Cardinal Health for Cell Therapy Supply (Zacks)
Apr-27-23 07:01AM	Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at ASCO (GlobeNewswire) +5.49%
07:00AM	Autolus Therapeutics Selects Cardinal Health as U.S. Commercial Distribution Partner (GlobeNewswire)
Apr-26-23 04:01PM	Autolus Therapeutics Announces Publication in Molecular Therapy Nucleic Acids (GlobeNewswire) -5.20%
07:06AM	Autolus Therapeutics Announces Data from AUTO1/22 Trial in Pediatric Acute Lymphoblastic Leukemia in an Oral Presentation at the EBMT 49th Annual Meeting (GlobeNewswire)
Apr-25-23 07:00AM	Autolus Therapeutics to Host Virtual Capital Markets Day (GlobeNewswire)
Apr-20-23 07:00AM	Autolus Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023 (GlobeNewswire)
Apr-16-23 09:30AM	12 Best Low-Priced Growth Stocks To Buy (Insider Monkey)
Apr-14-23 11:08AM	Autolus Therapeutics (NASDAQ:AUTL) shareholders have endured a 79% loss from investing in the stock three years ago (Simply Wall St.)
Apr-04-23 07:00AM	Autolus Therapeutics Announces Publication in Molecular Therapy (GlobeNewswire) -6.19%
Mar-14-23 07:00AM	Autolus Therapeutics announces resignation of Chief Financial Officer (GlobeNewswire)
Mar-13-23 07:00AM	Autolus Therapeutics Has No Business Relationship with Silicon Valley Bank (GlobeNewswire) +6.32%
Mar-08-23 10:45PM	Autolus Therapeutics plc (NASDAQ:AUTL) Q4 2022 Earnings Call Transcript (Insider Monkey) +6.25%
03:22AM	Q4 2022 Autolus Therapeutics PLC Earnings Call (Thomson Reuters StreetEvents)
Mar-07-23 07:00AM	Autolus Therapeutics Reports Full Year 2022 Financial Results and Operational Progress (GlobeNewswire)
Feb-28-23 09:40AM	Has Acasti Pharma (ACST) Outpaced Other Medical Stocks This Year? (Zacks)
Feb-15-23 07:00AM	Autolus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 7, 2023 (GlobeNewswire)
Feb-08-23 11:05AM	2 Strong Buy Penny Stocks That Could Rally All the Way to $11 (or More) (TipRanks) +11.50%
Jan-24-23 09:40AM	Is Alaunos Therapeutics (TCRT) Outperforming Other Medical Stocks This Year? (Zacks)
Jan-23-23 05:49AM	Is Autolus Therapeutics (NASDAQ:AUTL) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jan-20-23 07:00AM	Autolus Therapeutics announces Board changes (GlobeNewswire) +5.26%
Jan-09-23 07:00AM	Autolus Therapeutics Announces Collaboration with Cabaletta Bio for Use of Autolus Safety Switch System in Cell Therapies for Autoimmune Disease (GlobeNewswire)
Dec-26-22 12:35PM	Individual investors account for 36% of Autolus Therapeutics plc's (NASDAQ:AUTL) ownership, while private equity firms account for 32% (Simply Wall St.)
Dec-21-22 04:01PM	Autolus Announces Partial Exercise of Underwriters' Option to Purchase Additional ADSs (GlobeNewswire)
Dec-12-22 10:00AM	Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022 (GlobeNewswire)
Dec-09-22 11:31AM	Why Autolus Therapeutics Stock Is Crashing Today (Motley Fool) -38.13%
07:43AM	Autolus Therapeutics' Leukemia Trial Meets Primary Goal Of Remission Rate, Shares Fall After $150M Capital Raise (Benzinga)
Dec-08-22 09:11PM	Autolus Announces Pricing of Public Offering (GlobeNewswire)
04:03PM	Autolus Announces Proposed Public Offering in the United States (GlobeNewswire)
04:02PM	Autolus Therapeutics to Receive $70 Million in Milestone Payments from Blackstone Life Sciences (GlobeNewswire)
04:01PM	Autolus Therapeutics announces pivotal Phase 2 FELIX clinical trial has met primary endpoint at interim analysis (GlobeNewswire)
Nov-30-22 07:00AM	Autolus Therapeutics announces handover of first clean rooms of new Stevenage, UK, manufacturing facility (GlobeNewswire) +5.18%
Nov-29-22 11:35AM	Autolus Therapeutics plc's (NASDAQ:AUTL) Intrinsic Value Is Potentially 21% Below Its Share Price (Simply Wall St.)
Nov-09-22 05:16AM	Autolus Therapeutics Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS In Line (Simply Wall St.)
Nov-05-22 08:35AM	Shareholders in Autolus Therapeutics (NASDAQ:AUTL) have lost 81%, as stock drops 22% this past week (Simply Wall St.)
Nov-03-22 09:31AM	Autolus Therapeutics to Present Three Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022 (GlobeNewswire) -5.04%
07:00AM	Autolus Therapeutics Reports Third Quarter 2022 Financial Results and Operational Progress (GlobeNewswire)
Oct-21-22 07:00AM	Autolus Therapeutics to Report Third Quarter 2022 Financial Results on November 3, 2022 (GlobeNewswire)
Oct-12-22 11:30AM	Moderna In-Licenses Autolus' Technology For mRNA-Based Cancer Therapeutics (Benzinga) +9.73%
07:00AM	Moderna exercises option to license proprietary targeting technology from Autolus (GlobeNewswire)
Oct-04-22 10:21AM	Autolus Therapeutics Stock Jumps After Bristol Myers Pact For Safety Switch System (Benzinga) +25.69%
07:00AM	Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus Proprietary Safety Switch System (GlobeNewswire)
Sep-20-22 07:30AM	Gain Therapeutics Announces Promotion of Matthias Alder to Chief Executive Officer (GlobeNewswire) -6.64%
Aug-04-22 07:00AM	Autolus Therapeutics Reports Second Quarter 2022 Financial Results and Operational Progress (GlobeNewswire) +16.49%
Jul-21-22 07:54AM	Correction - Autolus Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022 (GlobeNewswire) -7.59%
07:00AM	Autolus Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022 (GlobeNewswire)
Jul-11-22 06:00AM	Is Autolus Therapeutics (NASDAQ:AUTL) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AUTL

Autolus Therapeutics plc ADR

Upgrade your FINVIZ experience